Sebastian Haferkampf

16PUBLICATIONS
107CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|May 27, 2026
Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate.

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Feb 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Michael Weichenthal, Dirk Debus, Lisa Zimmer

|Mar 06, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).

Adi Diab, Paolo A Ascierto, Michele Maio

|Dec 17, 2024
Impact of Patient's Age and Physician's Professional Background on the Number Needed to Treat in Malignant Melanoma Detection.

Laura Schreieder, Veronika Zenderowski, Mark Berneburg

Pageof 3

Frequent Collaborators

5 joint publications

Michael Weichenthal

4 joint publications

Jochen Utikal

4 joint publications

Dennis Niebel

4 joint publications

Axel Hauschild